Disease · MONDO_0010150
head and neck squamous cell carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. head and neck squamous cell carcinoma. Diseases, record MONDO_0010150. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0010150
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
HNSCC, SCCHN, craniocervical region squamous cell carcinoma, squamous cell carcinoma of head and neck, squamous cell carcinoma of the head and neck, squamous cell carcinoma, head and neck, somatic, squamous cell carcinomas of head and neck
- Open Targets
- Highest stage of its drugs
- Approval, for 4 of its 424 drugs, from ClinicalTrials.gov, EMA Human Drugs and FDA
- Open Targets
Drugs424
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Approval | EMA Human Drugs | 198 | 197 | 197 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Approval | EMA Human Drugs | 75 | 74 | 74 | Drugs and targets |
| GEFITINIB | CHEMBL939 | Small molecule | Approval | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| COSIBELIMAB | CHEMBL4297729 | Antibody | Approval | FDA | 1 | 0 | 0 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 242 | 242 | 242 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 3 | ClinicalTrials.gov | 194 | 194 | 194 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 120 | 120 | 102 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 106 | 106 | 105 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 97 | 97 | 97 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 84 | 84 | 83 | Drugs and targets |
1 to 10 of 424
See all 424 drugsTargets381
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 22 | Epidermal growth factor receptor erbB1 antagonist; Epidermal growth factor receptor erbB1 binding agent; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/1956 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 20 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Approval | https://conductscience.org/library/genes/5133 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 16 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 12 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 11 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| ERBB2 | Epidermal growth factor receptor | 10 | Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 3 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 10 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| TUBA1A | Tubulin | 10 | Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 10 | Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 10 | Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
1 to 10 of 381
See all 381 targetsTrials1,056
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 17 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01968109 | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Phase 1/2 | 1,482 | 2026-01-06 | Neoplasms by Site | NIVOLUMAB, RELATLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02741570 | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Phase 3 | 947 | 2022-05-03 | Head and Neck Cancer | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02358031 | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | Phase 3 | 882 | 2020-02-17 | Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | CARBOPLATIN, CISPLATIN, FLUOROURACIL, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03040999 | Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) | Phase 3 | 804 | 2023-06-08 | Head and Neck Neoplasms | CISPLATIN, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00047008 | Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer | Phase 3 | 743 | 2014-08-15 | Head and Neck Cancer | CISPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02369874 | Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer | Phase 3 | 736 | 2019-10-03 | Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN | DURVALUMAB, TREMELIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04459715 | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) | Phase 3 | 730 | 2025-10-08 | Squamous Cell Carcinoma of the Head and Neck | XEVINAPANT | Its record names the disease | ClinicalTrials.gov |
| NCT03765918 | Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | Phase 3 | 714 | 2025-08-20 | Head and Neck Neoplasms | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00956007 | RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer | Phase 3 | 702 | 2024-05-28 | Head and Neck Cancer | CETUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02952586 | Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) | Phase 3 | 697 | 2021-02-24 | Squamous Cell Carcinoma of the Head and Neck | AVELUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 1,056
See all 1,056 trialsComparisons in its trials223
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nivolumab + Ipilimumab vs EXTREME Regimen: deaths from any cause | 388 of 472 | 406 of 475 | 947 | NCT02741570 | Trial comparisons |
| Nivolumab + Ipilimumab vs EXTREME Regimen: serious adverse events | 313 of 468 | 290 of 441 | 909 | NCT02741570 | Trial comparisons |
| Pembrolizumab + CRT + Pembrolizumab vs Placebo + CRT + Placebo: deaths from any cause | 156 of 402 | 178 of 402 | 804 | NCT03040999 | Trial comparisons |
| Pembrolizumab + CRT + Pembrolizumab vs Placebo + CRT + Placebo: Number of Participants Who Discontinued Study Drug Due to an AE | 163 of 398 | 132 of 398 | 796 | NCT03040999 | Trial comparisons |
| Pembrolizumab + CRT + Pembrolizumab vs Placebo + CRT + Placebo: Number of Participants Who Experienced an Adverse Event (AE) | 398 of 398 | 397 of 398 | 796 | NCT03040999 | Trial comparisons |
| Pembrolizumab + CRT + Pembrolizumab vs Placebo + CRT + Placebo: serious adverse events | 245 of 398 | 197 of 398 | 796 | NCT03040999 | Trial comparisons |
| Sequence 1: Debio 1143 + CRT vs Sequence 2: Placebo + CRT: deaths from any cause | 111 of 364 | 93 of 366 | 730 | NCT04459715 | Trial comparisons |
| Standard Fractionation RT + Cisplatin vs Accelerated Fractionation RT + Cisplatin: serious adverse events | 293 of 361 | 279 of 360 | 721 | NCT00047008 | Trial comparisons |
| Sequence 1: Debio 1143 + CRT vs Sequence 2: Placebo + CRT: Number of Participants With Severity of Grade Greater or Equal to 3 TEAEs | 320 of 364 | 286 of 356 | 720 | NCT04459715 | Trial comparisons |
| Sequence 1: Debio 1143 + CRT vs Sequence 2: Placebo + CRT: serious adverse events | 194 of 364 | 129 of 356 | 720 | NCT04459715 | Trial comparisons |
1 to 10 of 223
See all 223 comparisons in its trialsPapers from its trials477
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010150
GET https://conductscience.org/api/diseases/v1/MONDO_0010150/drugs?page=2